

REMARKS

In the Office Action dated December 19, 2007, the Examiner alleged that this application contains more than one invention and requested restriction to one of the following groups of the inventions:

I. Claims 1-16, drawn to a composition comprising a metal-chelating ligand including a tetraazacyclododecane macrocycle ring core and at least two non-identical substituents covalently bonded to the ring core, wherein each of the at least two non-identical substituents contain a group capable of binding to a cell receptor.

II. Claims, 17-21, drawn to a composition comprising a metal-chelating ligand including tetraazacyclododecane macrocycle having one or more alkyl carboxylic acids or salts thereof appended to the ring nitrogens and a guanidine substituent covalently bonded to a ring nitrogen of the metal-chelating ligand via an alkyl linking group, an alkyl carbonyl linking group, or an alkyl amide linking group.

III. Claims 22-24 drawn to a method of inhibiting tumor cell growth by administering to the tumor cells an effective amount of a composition including a compound having a metal-chelating ligand including tetraazacyclododecane macrocycle having one or more alkyl carboxylic acids or salts thereof appended to the ring nitrogens and alpha-beta receptor binding ligand covalently bonded to a ring nitrogen of the metal-chelating ligand via an alkyl group linking group, an alkyl carbonyl linking group, an alkyl carbonyl linking group, or an alkyl amide linking group.

IV. Claims 25-27, drawn to a method of inhibiting tumor cell growth, said method comprising administering to the cells a metal-chelating ligand including tetraazacyclododecane macrocycle ring having one or more alkyl carboxylic acids or salts thereof appended to the ring nitrogen(s), and a guanidine substituent covalently bonded to a ring nitrogen of the metal chelating ligand via an alkyl linking group, an alkyl carbonyl linking group, or an alkyl amide linking group.

In response to this Restriction Requirement, the Applicant hereby elects, without traverse, the Group II invention (claims 17-21), drawn to a composition comprising a metal-chelating ligand including tetraazacyclododecane macrocycle having one or more alkyl carboxylic acids or salts thereof appended to the ring nitrogens and a guanidine substituent covalently bonded to a ring nitrogen of the metal-chelating ligand via an alkyl linking group, an alkyl carbonyl linking group, or an alkyl amide linking group. As a result, claims 1-16, 22-24, and 25-27 have been withdrawn for consideration in a potential divisional application.

In addition, the Office Action includes a requirement for an election of species. Applicant elects as the species to be examined the species illustrated by the structure in Fig. 16 designated as Lot A024-16Y.

Should applicant's election require further clarification, the Examiner is invited to telephone the undersigned attorney.

Respectfully submitted,

By: Edward E. Sowers
Edward E. Sowers, Reg. No. 36,015
Woodard, Emhardt, Naughton
Moriarty & McNett
111 Monument Circle, Suite 3700
Indianapolis, IN 46204-5137
(317) 634-3456